vs
Apellis Pharmaceuticals, Inc.（APLS）与Claritev Corp（CTEV）财务数据对比。点击上方公司名可切换其他公司
Claritev Corp的季度营收约是Apellis Pharmaceuticals, Inc.的1.2倍（$246.6M vs $199.9M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -32.7%，领先3.2%），Claritev Corp同比增速更快（6.2% vs -5.9%），Claritev Corp自由现金流更多（$36.4M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 2.5%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
APLS vs CTEV — 直观对比
营收规模更大
CTEV
是对方的1.2倍
$199.9M
营收增速更快
CTEV
高出12.1%
-5.9%
净利率更高
APLS
高出3.2%
-32.7%
自由现金流更多
CTEV
多$50.7M
$-14.3M
两年增速更快
APLS
近两年复合增速
2.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $246.6M |
| 净利润 | $-59.0M | $-80.6M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -3.1% |
| 净利率 | -29.5% | -32.7% |
| 营收同比 | -5.9% | 6.2% |
| 净利润同比 | -62.2% | 41.6% |
| 每股收益（稀释后） | $-0.40 | $-4.88 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCTEV
| Q4 25 | $199.9M | $246.6M | ||
| Q3 25 | $458.6M | $246.0M | ||
| Q2 25 | $178.5M | $241.6M | ||
| Q1 25 | $166.8M | $231.3M | ||
| Q4 24 | $212.5M | $232.1M | ||
| Q3 24 | $196.8M | $230.5M | ||
| Q2 24 | $199.7M | $233.5M | ||
| Q1 24 | $172.3M | $234.5M |
净利润APLSCTEV
| Q4 25 | $-59.0M | $-80.6M | ||
| Q3 25 | $215.7M | $-69.8M | ||
| Q2 25 | $-42.2M | $-62.6M | ||
| Q1 25 | $-92.2M | $-71.3M | ||
| Q4 24 | $-36.4M | $-138.0M | ||
| Q3 24 | $-57.4M | $-391.4M | ||
| Q2 24 | $-37.7M | $-576.7M | ||
| Q1 24 | $-66.4M | $-539.7M |
营业利润率APLSCTEV
| Q4 25 | -25.6% | -3.1% | ||
| Q3 25 | 48.7% | 4.1% | ||
| Q2 25 | -18.6% | 6.9% | ||
| Q1 25 | -50.0% | 4.2% | ||
| Q4 24 | -12.3% | -17.8% | ||
| Q3 24 | -24.0% | -146.7% | ||
| Q2 24 | -14.7% | -224.4% | ||
| Q1 24 | -36.0% | -207.4% |
净利率APLSCTEV
| Q4 25 | -29.5% | -32.7% | ||
| Q3 25 | 47.0% | -28.4% | ||
| Q2 25 | -23.6% | -25.9% | ||
| Q1 25 | -55.3% | -30.8% | ||
| Q4 24 | -17.1% | -59.4% | ||
| Q3 24 | -29.2% | -169.8% | ||
| Q2 24 | -18.9% | -247.0% | ||
| Q1 24 | -38.5% | -230.1% |
每股收益（稀释后）APLSCTEV
| Q4 25 | $-0.40 | $-4.88 | ||
| Q3 25 | $1.67 | $-4.23 | ||
| Q2 25 | $-0.33 | $-3.81 | ||
| Q1 25 | $-0.74 | $-4.38 | ||
| Q4 24 | $-0.30 | $-8.49 | ||
| Q3 24 | $-0.46 | $-24.25 | ||
| Q2 24 | $-0.30 | $-35.78 | ||
| Q1 24 | $-0.54 | $-33.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $16.8M |
| 总债务越低越好 | — | $4.6B |
| 股东权益账面价值 | $370.1M | $-173.9M |
| 总资产 | $1.1B | $4.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCTEV
| Q4 25 | $466.2M | $16.8M | ||
| Q3 25 | $479.2M | $39.2M | ||
| Q2 25 | $370.0M | $56.4M | ||
| Q1 25 | $358.4M | $23.1M | ||
| Q4 24 | $411.3M | $16.8M | ||
| Q3 24 | $396.9M | $86.6M | ||
| Q2 24 | $360.1M | $48.8M | ||
| Q1 24 | $325.9M | $58.7M |
总债务APLSCTEV
| Q4 25 | — | $4.6B | ||
| Q3 25 | — | $4.5B | ||
| Q2 25 | — | $4.5B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | — | $4.5B | ||
| Q2 24 | — | $4.5B | ||
| Q1 24 | $93.1M | $4.5B |
股东权益APLSCTEV
| Q4 25 | $370.1M | $-173.9M | ||
| Q3 25 | $401.2M | $-101.8M | ||
| Q2 25 | $156.3M | $-39.9M | ||
| Q1 25 | $164.2M | $14.8M | ||
| Q4 24 | $228.5M | $84.0M | ||
| Q3 24 | $237.1M | $207.6M | ||
| Q2 24 | $264.3M | $603.4M | ||
| Q1 24 | $266.7M | $1.2B |
总资产APLSCTEV
| Q4 25 | $1.1B | $4.9B | ||
| Q3 25 | $1.1B | $5.0B | ||
| Q2 25 | $821.4M | $5.1B | ||
| Q1 25 | $807.3M | $5.1B | ||
| Q4 24 | $885.1M | $5.2B | ||
| Q3 24 | $901.9M | $5.3B | ||
| Q2 24 | $904.5M | $5.7B | ||
| Q1 24 | $831.9M | $6.4B |
负债/权益比APLSCTEV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 304.87× | ||
| Q4 24 | — | 53.67× | ||
| Q3 24 | — | 21.73× | ||
| Q2 24 | — | 7.48× | ||
| Q1 24 | 0.35× | 3.85× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $66.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $36.4M |
| 自由现金流率自由现金流/营收 | -7.1% | 14.8% |
| 资本支出强度资本支出/营收 | 0.1% | 12.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-12.3M |
8季度趋势，按日历期对齐
经营现金流APLSCTEV
| Q4 25 | $-14.2M | $66.3M | ||
| Q3 25 | $108.5M | $19.9M | ||
| Q2 25 | $4.4M | $61.2M | ||
| Q1 25 | $-53.4M | $-30.1M | ||
| Q4 24 | $19.4M | $-33.4M | ||
| Q3 24 | $34.1M | $72.8M | ||
| Q2 24 | $-8.3M | $18.5M | ||
| Q1 24 | $-133.0M | $49.7M |
自由现金流APLSCTEV
| Q4 25 | $-14.3M | $36.4M | ||
| Q3 25 | $108.3M | $-16.3M | ||
| Q2 25 | $4.4M | $36.6M | ||
| Q1 25 | $-53.4M | $-68.9M | ||
| Q4 24 | $19.3M | $-63.8M | ||
| Q3 24 | — | $41.1M | ||
| Q2 24 | $-8.4M | $-7.0M | ||
| Q1 24 | $-133.3M | $19.2M |
自由现金流率APLSCTEV
| Q4 25 | -7.1% | 14.8% | ||
| Q3 25 | 23.6% | -6.6% | ||
| Q2 25 | 2.5% | 15.2% | ||
| Q1 25 | -32.0% | -29.8% | ||
| Q4 24 | 9.1% | -27.5% | ||
| Q3 24 | — | 17.8% | ||
| Q2 24 | -4.2% | -3.0% | ||
| Q1 24 | -77.3% | 8.2% |
资本支出强度APLSCTEV
| Q4 25 | 0.1% | 12.1% | ||
| Q3 25 | 0.0% | 14.7% | ||
| Q2 25 | 0.0% | 10.2% | ||
| Q1 25 | 0.0% | 16.8% | ||
| Q4 24 | 0.0% | 13.1% | ||
| Q3 24 | 0.0% | 13.8% | ||
| Q2 24 | 0.0% | 10.9% | ||
| Q1 24 | 0.2% | 13.0% |
现金转化率APLSCTEV
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CTEV
暂无分部数据
